Logo image of TLIS

TALIS BIOMEDICAL CORP (TLIS) Stock Analyst Ratings

NASDAQ:TLIS - Nasdaq - US87424L2079 - Common Stock - Currency: USD

4.38  +0.22 (+5.29%)

After market: 4.49 +0.11 (+2.51%)

Buy % Consensus

37

ChartMill assigns a Buy % Consensus number of 37% to TLIS. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 5.1. This target is 16.44% above the current price.
TLIS was analyzed by 6 analysts. The buy percentage consensus is at 37. So analysts seem to be rather negative about TLIS.
In the previous month the buy percentage consensus was at a similar level.
TLIS was analyzed by 6 analysts. More opinions would make the average more meaningful.

Related screens

TLIS Historical Analyst RatingsTLIS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -32 -29 -26 -23 -20 -17 -14 -11 -8 -5 -2 2 4 6 8

Price Target & Forecast

Price Low Median Mean High 4.385.055.105.105.25 - 15.30% 16.44% 16.44% 19.86%

Related screens

TLIS Current Analyst RatingTLIS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2023-08-16 BTIG Maintains Sell -> Sell
2022-01-07 B of A Securities Downgrade Neutral -> Underperform
2021-09-27 JP Morgan Downgrade Neutral -> Underweight
2021-08-12 Piper Sandler Downgrade Overweight -> Neutral
2021-08-11 JP Morgan Downgrade Overweight -> Neutral
2021-03-09 BTIG Initiate Buy
2021-03-09 JP Morgan Initiate Overweight
2021-03-09 B of A Securities Initiate Neutral
2021-03-09 Piper Sandler Initiate Overweight